Barzolvolimab - Celldex Therapeutics Inc
Alternative Names: Anti-KIT monoclonal antibody - Celldex Therapeutics; CDX-0159Latest Information Update: 28 Jun 2025
At a glance
- Originator University of Toronto; Yale University School of Medicine
- Developer Celldex Therapeutics Inc
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Proto-oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic urticaria
- Phase II Atopic dermatitis; Eosinophilic oesophagitis; Prurigo nodularis
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Prurigo-nodularis(In the elderly, Treatment-experienced, In adults) in Germany (SC)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Prurigo-nodularis(In the elderly, Treatment-experienced, In adults) in Poland (SC)
- 14 Jun 2025 Efficacy data from a phase II trial in Chronic spontaneous urticaria released by Celldex Therapeutics